SpringWorks Therapeutics reported net product revenue of $49.3 million for OGSIVEO in the third quarter of 2024, representing a 23% quarter-over-quarter growth. This performance reflects continued demand and new patient starts for the desmoid tumor therapy.
The company maintained a strong financial position, ending September 30, 2024, with $498 million in cash, cash equivalents, and marketable securities. SpringWorks Therapeutics expects this capital to fund its operations through profitability, which is anticipated in the first half of 2026.
Significant progress was also made in the pipeline, with the New Drug Application for mirdametinib in NF1-PN granted FDA Priority Review, setting a PDUFA target action date of February 28, 2025. The European Medicines Agency also validated the Marketing Authorization Application for mirdametinib, advancing its potential approval in Europe.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.